| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Prakash Chinnaiyan, Shyhmin Huang, Geetha Vallabhaneni, Eric Armstrong, Sooryanarayana Varambally, Scott A Tomlins, Arul M Chinnaiyan, Paul M Harar. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer research. vol 65. issue 8. 2005-06-03. PMID:15833866. |
erlotinib enhances the induction of apoptosis, inhibits egfr autophosphorylation and rad51 expression following radiation exposure, and promotes an increase in radiosensitivity. |
2005-06-03 |
2023-08-12 |
mouse |
| S Park, C D Jame. ECop (EGFR-coamplified and overexpressed protein), a novel protein, regulates NF-kappaB transcriptional activity and associated apoptotic response in an IkappaBalpha-dependent manner. Oncogene. vol 24. issue 15. 2005-05-16. PMID:15735698. |
these results suggest that ecop is a key regulator of nf-kappab signaling, and that high-level, amplification-mediated ecop expression, such as that occurring in tumors with amplified egfr, could contribute to resistance to apoptosis. |
2005-05-16 |
2023-08-12 |
Not clear |
| L Minerva Burgos Fuster, Alan B Sandle. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clinical lung cancer. vol 6 Suppl 1. 2005-05-10. PMID:15638954. |
this includes the epidermal growth factor receptor (egfr), which is known to potentiate tumor cell proliferation and metastases, while also attenuating apoptosis. |
2005-05-10 |
2023-08-12 |
Not clear |
| Ingirídur Skírnisdóttir, Tomas Seidal, Mats G Karlsson, Bengt Sorb. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. International journal of oncology. vol 26. issue 1. 2005-05-02. PMID:15586238. |
the apoptosis regulators p53, bcl-2 and bax, and the growth factor receptors egfr and her-2/neu were analyzed by immunohistochemical techniques and dna analysis was performed by flow cytometry. |
2005-05-02 |
2023-08-12 |
Not clear |
| J-L Fischel, P Formento, G Milan. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. British journal of cancer. vol 92. issue 6. 2005-04-28. PMID:15756277. |
these antagonistic effects were corroborated by molecular changes in apoptosis (parp) and egfr signalling (phospho-p42-44). |
2005-04-28 |
2023-08-12 |
human |
| Edwin Bremer, Douwe F Samplonius, Linda van Genne, Marike H Dijkstra, Bart Jan Kroesen, Lou F M H de Leij, Wijnand Helfric. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. The Journal of biological chemistry. vol 280. issue 11. 2005-04-25. PMID:15644326. |
simultaneous inhibition of epidermal growth factor receptor (egfr) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (trail) receptor-mediated apoptosis induction by an scfv:strail fusion protein with specificity for human egfr. |
2005-04-25 |
2023-08-12 |
human |
| Edwin Bremer, Douwe F Samplonius, Linda van Genne, Marike H Dijkstra, Bart Jan Kroesen, Lou F M H de Leij, Wijnand Helfric. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. The Journal of biological chemistry. vol 280. issue 11. 2005-04-25. PMID:15644326. |
epidermal growth factor receptor (egfr) signaling inhibition by monoclonal antibodies and egfr-specific tyrosine kinase inhibitors has shown clinical efficacy in cancer by restoring susceptibility of tumor cells to therapeutic apoptosis induction. |
2005-04-25 |
2023-08-12 |
human |
| Edwin Bremer, Douwe F Samplonius, Linda van Genne, Marike H Dijkstra, Bart Jan Kroesen, Lou F M H de Leij, Wijnand Helfric. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. The Journal of biological chemistry. vol 280. issue 11. 2005-04-25. PMID:15644326. |
here we present a novel approach that combines egfr-signaling inhibition with target cell-restricted apoptosis induction using a trail fusion protein with engineered specificity for egfr. |
2005-04-25 |
2023-08-12 |
human |
| Adnan Tanović, Vicente Alfar. Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs of today (Barcelona, Spain : 1998). vol 40. issue 10. 2005-04-08. PMID:15605116. |
gefitinib is an orally active, epidermal growth factor receptor (egfr)-tyrosine kinase (egfr-tk) reversible inhibitor which blocks egfr phosphorylation and subsequent signal transduction pathways involved in proliferation, metastasis, angiogenesis and apoptosis inhibition. |
2005-04-08 |
2023-08-12 |
Not clear |
| Laura P Stabile, Jennifer S Lyker, Christopher T Gubish, Weiping Zhang, Jennifer R Grandis, Jill M Siegfrie. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer research. vol 65. issue 4. 2005-04-04. PMID:15735034. |
cell growth and apoptosis were examined in several nsclc lines that express varying amounts of erbeta, egfr, and neu but no full-length eralpha. |
2005-04-04 |
2023-08-12 |
mouse |
| G Tortora, R Bianco, G Daniel. Strategies for multiple signalling inhibition. Journal of chemotherapy (Florence, Italy). vol 16 Suppl 4. 2005-04-01. PMID:15688608. |
cancer cells hyperactivate signalling molecules, including egfr, akt and the angiogenic factor vegf to escape apoptosis, thus contributing also to resistance to treatment. |
2005-04-01 |
2023-08-12 |
Not clear |
| Roberto Bianco, Fortunato Ciardiello, Giampaolo Tortor. Chemosensitization by antisense oligonucleotides targeting MDM2. Current cancer drug targets. vol 5. issue 1. 2005-03-29. PMID:15720189. |
moreover, mdm2 antisense oligonucleotides potentiate the effect of epidermal growth factor receptor (egfr) inhibitors by affecting in vitro and in vivo proliferation, apoptosis and protein expression in hormone-refractory and hormone-dependent human prostate cancer cells. |
2005-03-29 |
2023-08-12 |
human |
| Rodney B Luwor, Hong-Jian Zhu, Francesca Walker, Angela A Vitali, Rushika M Perera, Antony W Burgess, Andrew M Scott, Terrance G John. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene. vol 23. issue 36. 2005-03-25. PMID:15221011. |
expression of the de2-7 egfr enhanced the survival of baf/3 cells in the absence of il-3 by reducing apoptosis in a phosphatidylinositol 3-kinase (pi3-k)-dependent manner. |
2005-03-25 |
2023-08-12 |
Not clear |
| A Craig Lockhart, Craig Lockhart, Jordan D Berli. The epidermal growth factor receptor as a target for colorectal cancer therapy. Seminars in oncology. vol 32. issue 1. 2005-03-22. PMID:15726506. |
the egfr axis is activated by a variety of ligands that are crucial in the formation and propagation of many tumors, including colorectal cancer, through their effects on cell signaling pathways, cellular proliferation, control of apoptosis, and angiogenesis. |
2005-03-22 |
2023-08-12 |
Not clear |
| Joseph Amann, Shailaja Kalyankrishna, Pierre P Massion, Joyce E Ohm, Luc Girard, Hisayuki Shigematsu, Michael Peyton, Denise Juroske, Yuhui Huang, J Stuart Salmon, Young H Kim, Jonathan R Pollack, Kiyoshi Yanagisawa, Adi Gazdar, John D Minna, Jonathan M Kurie, David P Carbon. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer research. vol 65. issue 1. 2005-03-02. PMID:15665299. |
treatment with the specific egfr tyrosine kinase inhibitors (tki) gefitinib or erlotinib or the egfr inhibitory antibody cetuximab induced apoptosis of hcc827, a nsclc cell line with egfr gene amplification and an exon 19 deletion. |
2005-03-02 |
2023-08-12 |
Not clear |
| Christelle Souriau, Julie Rothacker, Hennie R Hoogenboom, Edouard Nic. Human antibody fragments specific for the epidermal growth factor receptor selected from large non-immunised phage display libraries. Growth factors (Chur, Switzerland). vol 22. issue 3. 2005-02-25. PMID:15518242. |
antibodies to egfr have been shown to display anti-tumour effects mediated in part by inhibition of cellular proliferation and angiogenesis, and by enhancement of apoptosis. |
2005-02-25 |
2023-08-12 |
human |
| Bronislaw L Slomiany, Amalia Slomian. Role of epidermal growth factor receptor transactivation in PPAR gamma-dependent suppression of Helicobacter pylori interference with gastric mucin synthesis. Inflammopharmacology. vol 12. issue 2. 2005-02-17. PMID:15265318. |
moreover, the inhibitory effect of ciglitazone on the lps-induced reduction in mucin synthesis and upregulation in apoptosis, caspase-3 activity and no generation was countered by pp2, a selective inhibitor of tyrosine kinase src responsible for ligand-independent egfr transactivation. |
2005-02-17 |
2023-08-12 |
Not clear |
| Vladimir N Ivanov, Tom K He. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene. vol 24. issue 4. 2005-02-15. PMID:15580309. |
combined treatment with egfr inhibitors and arsenite upregulated apoptosis in human egfr-positive melanomas: a role of suppression of the pi3k-akt pathway. |
2005-02-15 |
2023-08-12 |
human |
| Vladimir N Ivanov, Tom K He. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene. vol 24. issue 4. 2005-02-15. PMID:15580309. |
since egfr signaling operates via activation of the pi3k-akt and mek-erk pathways, we suggested that the combination of arsenite and egfr inhibitors might also effectively induce apoptosis in melanoma. |
2005-02-15 |
2023-08-12 |
human |
| Vladimir N Ivanov, Tom K He. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene. vol 24. issue 4. 2005-02-15. PMID:15580309. |
here, we demonstrate that a moderate concentration of arsenite (5-10 mum) indeed upregulates apoptosis induced by egfr inhibitors in egfr-positive melanomas. |
2005-02-15 |
2023-08-12 |
human |